Refractory Metastatic Colorectal Cancer
Oncology
4
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 2 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Taiho OncologyNJ - Princeton
2 programs1
1
Trifluridine/TipiracilPhase 31 trial
TAS-102Phase 21 trial
Active Trials
DelcathQUEENSBURY, NY
1 program1
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus BevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Taiho OncologyTrifluridine/Tipiracil
DelcathMelphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
Qilu PharmaceuticalBevacizumab
Taiho OncologyTAS-102
Clinical Trials (4)
Total enrollment: 90 patients across 4 trials
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
Start: Nov 2020Est. completion: Sep 2023
Phase 3Completed
NCT06607458DelcathMelphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Start: Aug 2025Est. completion: Oct 202790 patients
Phase 2Recruiting
QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer
Start: Sep 2020Est. completion: Feb 2022
Phase 2Unknown
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Start: Aug 2016Est. completion: Sep 2017
Phase 2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
1h ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
1h ago
Office Administrator
SystImmune
1h ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
1h ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
1h ago
Working Student Active Sourcing Support (m/f/d)
Mindpeak
Hamburg
1h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 90 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space